A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects with BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib
Latest Information Update: 04 Dec 2024
At a glance
- Drugs Cemiplimab (Primary) ; Dabrafenib; Trametinib
- Indications Thyroid cancer
- Focus Therapeutic Use
Most Recent Events
- 02 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 19 Nov 2024 Planned number of patients changed from 15 to 16.
- 03 Jul 2024 Planned End Date changed from 20 Jun 2024 to 20 Jun 2025.